<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="626">
  <stage>Registered</stage>
  <submitdate>3/08/2005</submitdate>
  <approvaldate>3/08/2005</approvaldate>
  <nctid>NCT00126880</nctid>
  <trial_identification>
    <studytitle>AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV</studytitle>
    <scientifictitle>A Phase II, Randomised, Double-blind, Dose-ranging Study of AVX754 Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AVX-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AVX754
Treatment: drugs - 3TC

Experimental: 600mg BID ATC - 600mg BID ATC

Experimental: 800mg BID ATC - 800mg BID ATC

Active Comparator: 150mg BID 3TC - 150mg BID 3TC


Treatment: drugs: AVX754
apricitabine, 600mg BID or 800mg BID

Treatment: drugs: 3TC
3TC, 150mg BID

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in HIV RNA levels at day 21</outcome>
      <timepoint>day 21</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time-weighted average change from baseline in HIV RNA levels through 21 days</outcome>
      <timepoint>21 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in HIV RNA levels at days 7, 14, 21</outcome>
      <timepoint>days 7, 14, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with HIV RNA levels &lt;400 or &lt;50 at days 7, 14, 21, and weeks 24 and 48</outcome>
      <timepoint>days 7, 14, 21, and weeks 24 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline and change in ratio of CD4+ and CD8+ cells at day 21 and weeks 24 and 48</outcome>
      <timepoint>day 21 and weeks 24 and 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  HIV-1 infected

          -  M184V mutation in reverse transcriptase

          -  Currently taking lamivudine

          -  Viral load &gt;2000 copies/ml</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hepatitis B surface antigen positive

          -  Pregnant or breastfeeding females

          -  Hepatitis C RNA positive and requiring treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>52</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Avexa (co-ordinating sites in Australia and Argentina) - Melbourne</hospital>
    <postcode>3121 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avexa</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is
      in treating HIV-1 infected people who have failed treatment with lamivudine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00126880</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Susan W Cox, Ph D</name>
      <address>Avexa</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>